Symphogen A/S and Open Monoclonal Technology, Inc. Announce Collaboration
Published: Oct 15, 2013
COPENHAGEN, Denmark & PALO ALTO, Calif.--(BUSINESS WIRE)--Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, and Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic animals for development of human therapeutic antibodies, today announced an alliance that provides Symphogen with unlimited access to OMT’s OmniRat® and OmniMouse® platforms. Symphogen will use its proprietary B cell-based antibody identification technology, Symplex™, and access the diverse immune repertoires generated in OMT’s transgenic animals to develop novel human therapeutic candidates.
Help employers find you! Check out all the jobs and post your resume.